View Older Stories View More Recent Stories

Apr 27, 2018 07:05AM New Study Finds that 24 Percent of Women Seen in the Obstetrics-Gynecology Setting Met NCCN Guidelines for Hereditary Cancer Genetic Testing
Apr 27, 2018 07:05AM New Study Finds that 24 Percent of Women Seen in the Obstetrics-Gynecology Setting Met NCCN Guidelines for Hereditary Cancer Genetic Testing
Mar 1, 2018 07:05AM Myriad Genetics Demonstrates Strong Commitment to Preventing Hereditary Colon Cancer as Part of National Colorectal Cancer Awareness Month
Mar 1, 2018 07:05AM Myriad Genetics Demonstrates Strong Commitment to Preventing Hereditary Colon Cancer as Part of National Colorectal Cancer Awareness Month
Feb 15, 2018 11:24AM Myriad Genetics (MYGN) Reports Published Data Demonstrates EndoPredict (EPClin) Significantly Outperforms Oncotype DX Recurrence Score in Early-Stage Breast Cancer
Feb 15, 2018 11:15AM JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer
Feb 15, 2018 11:15AM JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer
Feb 7, 2018 07:05AM Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation
Feb 7, 2018 07:05AM Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation
Dec 11, 2017 06:07AM Myriad Genetics (MYGN) Reports Results From Two Important EndoPredict Studies
Dec 8, 2017 06:00PM Myriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer Symposium
Dec 8, 2017 06:00PM Myriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer Symposium
Dec 6, 2017 06:00PM Myriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium
Dec 6, 2017 06:00PM Myriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium
Oct 26, 2017 07:28AM Myriad Genetics (MYGN) Announces EndoPredict Shown in Second Study to be More Effective than Oncotype DX in Women with Intermediate Risk of Breast Cancer Recurrence
Oct 26, 2017 07:05AM EndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX® (RS) in Women with Intermediate Risk of Breast Cancer Recurrence
Oct 19, 2017 07:05AM GeneSight® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodiazepine Use
Sep 15, 2017 07:06AM Myriad Genetics (MYGN) Announces Positive Data Supporting New riskScore Test at NSGC
Sep 15, 2017 07:05AM Myriad Genetics Announces Positive Data Supporting New riskScore™ Test at the 36th Annual Conference of the National Society of Genetic Counselors
Sep 12, 2017 07:05AM Myriad Genetics to Present Three Studies at the 2017 National Society of Genetic Counselors Annual Conference
Jun 15, 2017 07:05AM Crescendo Bioscience Announces Results from a Meta-Analysis of Studies with Vectra® DA at the 2017 Annual European Congress of Rheumatology
Jun 8, 2017 07:10AM Myriad Genetics (MYGN) Says Six Studies with Vectra DA Will Be Presented at EULAR
Jun 8, 2017 07:05AM Crescendo Bioscience Announces Six Studies with Vectra® DA Will Be Presented at the 2017 Annual European Congress of Rheumatology
Jun 2, 2017 07:06AM Myriad Genetics (MYGN) Announces Results from 2,000 Patient Study of myRisk Hereditary Cancer Test at ASCO
Jun 2, 2017 07:05AM Myriad Genetics Announces Results from a Large 2,000 Patient Clinical Utility Study of Its myRisk® Hereditary Cancer Test at the 53rd Annual Meeting of ASCO
May 18, 2017 07:16AM Myriad Genetics (MYGN) to Present Seven Studies at ASCO
May 18, 2017 07:05AM Myriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting
May 12, 2017 07:06AM Myriad Genetics (MYGN) Says Data Shows Prolaris Test Accurately Predicts 10-Year Risk of Metastases in Men Treated for Prostate Cancer
May 12, 2017 07:05AM Myriad Genetics’ Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer
May 5, 2017 07:05AM Myriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting
Apr 17, 2017 07:11AM Myriad Genetics (MYGN) Says Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification
Apr 17, 2017 07:05AM Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public Database
Apr 5, 2017 07:08AM Myriad Genetics (MYGN) Announces Pivotal Study Results for myPath Melanoma Test Highlighted In Two Additional Scientific Publications
Apr 5, 2017 07:05AM Pivotal Study Results for Myriad’s myPath® Melanoma Test Highlighted In Two Additional Scientific Publications
Mar 20, 2017 07:13AM Myriad Genetics (MYGN) Announces Five Scientific Presentations at ACMG Meeting
Mar 20, 2017 07:05AM Myriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting
Mar 13, 2017 07:05AM Myriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast Cancer
Feb 23, 2017 07:05AM GeneSight® Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study Published in Clinical Therapeutics
Feb 17, 2017 07:05AM Myriad’s Prolaris® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer
Dec 9, 2016 07:05AM The EndoPredict® Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-Positive Breast Cancer Recurrence
Nov 28, 2016 07:05AM Myriad Genetics Will Present Results from Six Breast Cancer Studies at SABCS
Nov 12, 2016 04:30PM Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Presented at the American College of Rheumatology 2016 Annual Meeting
Oct 27, 2016 07:15AM Myriad Genetics (MYGN) Announces Upcoming Presentations of Strong myPath Melanoma Data
Oct 27, 2016 07:05AM The Myriad myPath® Melanoma Test Effectively Diagnosed Patients in the Largest Outcomes-Based Study for a Melanoma Diagnostic
Oct 18, 2016 07:05AM Myriad Genetics Teams Up with Project BioEYES to Advance STEM Education in Utah
Oct 10, 2016 12:57PM Unusual 11 Mid-Day Movers 10/10: (EGAS) (MCUR) (TSRO) Higher; (TWTR) (TWLO) (MYGN) Lower
Oct 7, 2016 02:15AM Myriad Announces Four Poster Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting
Jul 11, 2016 11:26AM Myriad Genetics (MYGN) Announces Publication of Positive EndoPredict Data in Breast Cancer; Says Primary Endpoint Met
Jul 11, 2016 11:25AM Myriad Announces Positive Results for an EndoPredict® Clinical Study Published in the Journal of the National Cancer Institute
Jun 6, 2016 07:15AM Myriad Genetics (MYGN) to Present Positive Data on myRisk Hereditary Cancer Test at ASCO
View More Recent Stories View Older Stories